Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥679.7bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥620.8bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥4.1bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥5.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥740.6bnat 2022-09-30Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥695.9bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥495.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥240.7bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥102.1bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥88.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.392021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.842021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥42.622021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.5%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥654.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥631.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥708.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥679.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥4.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥996m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-09-30¥45.5bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-09-30¥45.4bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥5m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-09-30¥819m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-09-30¥312m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-09-30¥597.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-09-30¥572.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.7bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥667m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥100m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥649.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥620.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 580
ItemContextValueUnit
Provision for bonuses sgaPrior1YTDDuration3340000000JPY
Provision for bonuses sgaCurrentYTDDuration3314000000JPY
Provision for directors bonuses sgaPrior1YTDDuration26000000JPY
Provision for directors bonuses sgaCurrentYTDDuration21000000JPY
Retirement benefit expenses sgaPrior1YTDDuration132000000JPY
Retirement benefit expenses sgaCurrentYTDDuration143000000JPY
Welfare expenses sgaPrior1YTDDuration3882000000JPY
Welfare expenses sgaCurrentYTDDuration3871000000JPY
Vehicle expenses sgaPrior1YTDDuration523000000JPY
Vehicle expenses sgaCurrentYTDDuration562000000JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration303000000JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration-83000000JPY
Depreciation sgaPrior1YTDDuration3028000000JPY
Depreciation sgaCurrentYTDDuration2746000000JPY
Amortization of goodwill sgaPrior1YTDDuration173000000JPY
Amortization of goodwill sgaCurrentYTDDuration149000000JPY
Rent expenses sgaPrior1YTDDuration4013000000JPY
Rent expenses sgaCurrentYTDDuration3997000000JPY
Taxes and dues sgaPrior1YTDDuration1044000000JPY
Taxes and dues sgaCurrentYTDDuration1039000000JPY
Exepences before deduction of temporary consumption tax payment sgaPrior1YTDDuration3134000000JPY
Exepences before deduction of temporary consumption tax payment sgaCurrentYTDDuration3153000000JPY
Other sgaPrior1YTDDuration8890000000JPY
Other sgaCurrentYTDDuration9770000000JPY
Selling general and administrative expensesPrior1YTDDuration48703000000JPY
Selling general and administrative expensesCurrentYTDDuration48823000000JPY
Operating incomePrior1YTDDuration1863000000JPY
Operating incomeCurrentYTDDuration4084000000JPY
Interest income noiPrior1YTDDuration32000000JPY
Interest income noiCurrentYTDDuration29000000JPY
Dividends income noiPrior1YTDDuration822000000JPY
Dividends income noiCurrentYTDDuration745000000JPY
Commission fee noiPrior1YTDDuration1566000000JPY
Commission fee noiCurrentYTDDuration1642000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration－JPY
Equity in earnings of affiliates noiCurrentYTDDuration71000000JPY
Other noiPrior1YTDDuration774000000JPY
Other noiCurrentYTDDuration1077000000JPY
Non operating incomePrior1YTDDuration3195000000JPY
Non operating incomeCurrentYTDDuration3566000000JPY
Interest expenses noePrior1YTDDuration38000000JPY
Interest expenses noeCurrentYTDDuration39000000JPY
Equity in losses of affiliates noePrior1YTDDuration6000000JPY
Equity in losses of affiliates noeCurrentYTDDuration－JPY
Rent expenses on real estates noePrior1YTDDuration99000000JPY
Rent expenses on real estates noeCurrentYTDDuration111000000JPY
Other noePrior1YTDDuration112000000JPY
Other noeCurrentYTDDuration106000000JPY
Non operating expensesPrior1YTDDuration257000000JPY
Non operating expensesCurrentYTDDuration257000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass